論文情報Publications

"For safe and adequate blood purification therapy in severe COVID-19 ‒ what we have learned so far." Katagiri D et al. Global Health Med (2022) 4:94-100

"When should PMX-DHP be introduced to improve COVID-19 prognosis?" Katagiri D et al. Ther Apher Dial (2022) 26:550-1

"The Rationale and Current Status of Endotoxin Adsorption in the Treatment of Septic Shock." Śmiechowicz J et al. J Clin Med (2022) 11:619

"Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study." Lee WY et al. Sci Rep (2021) 11:24132

"Polymyxin B and low-dose hydrocortisone treatment in a patient with uroseptic shock in a rural health unit." Arai T et al. Oxf Med Case Reports (2021) 11:433-5

"Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study." Fujimori K et al. Ann Intensive Care (2021) 11:141

"Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion for Micro-Preemie Infants with Septic Shock. Is Extended Duration Better than Early Start? Comment to the Letter to the Editor of Nishizaki and Colleagues" Mitaka C et al. Blood Purif (2022) 51:475-6

"Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion for Micro-Preemie Infants: Is Extended Duration Better than Early Start?" Nishizaki N et al. Blood Purif (2022) 51:472-4

"Acute respiratory distress syndrome caused by carbon monoxide poisoning and inhalation injury recovered after extracorporeal membrane oxygenation along with direct hemoperfusion with polymyxin B-immobilized fiber column: a case report." Jang JH et al. J Med Case Rep (2021) 15:456

"Endotoxin and Cytokine Sequential Hemoadsorption in Septic Shock and Multi-Organ Failure." Ruiz-Rodríguez JC. Blood Purif (Sep 7, 2021 online)

"Polymyxin B hemoperfusion in septic patients with acute myeloblastic and premyelocytic leukemia" De Simone L et al. Case Rep Int (2021) 10:100094Z06LS2021

"Studying polymyxin B-immobilized hemoperfusion therapy to remove endotoxin in infection with GN bacteria has conflicting results: We are not sure!" Honore PM H et al. J Crit Care (2021) 65:228-9

"Possibility of PMX-DHP therapy as a principal strategy against cytokine storm in COVID-19: Insights from reconstructed coagulation data." Ogawa H et al. J Clin Apher (2021) 36:785-6

"Is Exchange Transfusion for Severe Neonatal Infection Preferable to Polymyxin B-immobilized Fiber Column for Direct Hemoperfusion: Pros and Cons." Nishizaki N et al. Tohoku J Exp Med (2021) 254:141-2

"Whole Blood Gene Expression Profiling in Response to Treatment for Septic Shock: A Case Report." Akitomi S et al. Ann Clin Med Case Rep (2021) V6(17):1-5

"Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study." Mitaka C et al. Blood Purif (2022) 51:62-9

"Unsatisfactory Short-Term Neurodevelopmental Outcomes of Preterm Infants Who Received Polymyxin B-Immobilized Fiber Column-Direct Hemoperfusion for Septic Shock." Nishizaki N et al. Tohoku J. Exp. Med (2021) 253:275-81

"Effects of Polymyxin B Hemoperfusion in Patients with Sepsis Requiring Continuous Hemodiafiltration: Analysis of a Nationwide Administrative Database in Japan." Fujimori K et al. Ther Apher Dial (2021) 25:384-9

"Polymyxin B hemoperfusion therapy and extracorporeal CO2 removal in a patient with COVID-19: A case report." Luca M et al. Case Rep Int (2021) 10:100093Z06ML2021.

"Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia." Peerapornratana S et al. Blood Purif (2022) 51:47-54

"Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock." Mitaka C et al. Acute Crit Care (2021) 36:85-91

"PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series." Kuwana T et al. Infect Drug Resist (2021) 14:1305-10

"Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion." Leelayuwatanakul N et al. Respirol Case Rep (2021) 9:e0733　

"Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock." Shoji H et al. Int J Mol Sci (2021) 22:2228

"Uncertain Clinical Effect of Polymyxin B Hemoperfusion in Patients with Septic Acute Kidney Injury Requiring Continuous Renal Replacement Therapy." Lee JM et al. Shock (2021) 56:551-6

"Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan."Fujimori K et al. Blood Purification (2021) 50:560-5

"Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia." Shimoyama S et al. SAGE Open Medical Case Rep (2021) 9:1-5

"Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study."Fujimori K et al. Ann Intensive Care (2021) 11:141

"Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan."Fujimori K et al. Blood Purification (2021) 50:560-5　

"Effects of endotoxin adsorber hemoperfusion on sublingual microcirculation in patients with septic shock: a randomized controlled trial." Chen SH et al. (2020) Ann Intensive Care 10:80

"Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial." Klein DJ et al. Intensive Care Med (2018) Nov. 23

"The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients." Srisawat N et al. Crit Care (2018) 22:279

"Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.." Dellinger RP et al. JAMA (2018) 320:1455-63

"Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis." Fujii T et al. Intensive Care Med (2018) 44:167-78

"Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study." Nakamura Y et al. Crit Care (2017) 21:134

"Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis." Chang T et al. Crit Care Med (2017) 45:e858-e864

"Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. "Terayama T et al. Surg Infect (2017) 18:225-33

"Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry." Cutuli SL et al. Ann Intensive Care (2016) 6:77

"Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis." Iwagami M et al. Blood Purif (2016) 42:9-17

"Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial." Payen D et al. Intensive Care Med (2015) 41:975-84

"Rescue therapy with Polymyxin B hemoperfusion in high dose vasopressor therapy Refractory Septic Shock." Monti G et al. Minerva Anestesiol (2015) 81:516-2

"Endotoxin adsorption using polymyxin B immobilized　fiber cartridges in severe sepsis patients following cardiac surgery." Yaroustovsky M et al. Int J Artif Organs (2014) 37:299-307

"Postoperative Polymyxin B Hemoperfusion and Mortality in Patients With Abdominal Septic Shock: A Propensity-Matched Analysis." Iwagami M et al. Crit Care Med (2013) 42:1187-93

"Blood Purification and Mortality in Sepsis:A Meta-analysis of Randomized Trials." Zhou F et al. Crit Care Med (2013) 41:2209-2220

"Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial." Cruz DN et al. JAMA (2009) 301:2445-52

"Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors." Cantaluppi V et al. Intensive Care Med (2008) 34:1638-45

"Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review." Cruz DN et al. Crit Care (2007) 11:R47

"A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal Infection." Vincent JL et al. Shock (2005) 23:400-5

“Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock.” Mitaka C et al. Acute Crit Care (2021) 36:85-91

"Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock." Shoji H et al. Int J Mol Sci (2021) 22:2228

"Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients." Yamashita C et al. Contrib Nephrol (2018) 196:215-22

"History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock" Shimizu T et al. Ann Gastroenterol Surg (2017) 2017:1–9

"Polymyxin B hemoperfusion: a mechanistic perspective." Ronco C et al. Crit Care (2014) 18:309

"Immunomodulation in Sepsis: The Role of Endotoxin Removal by Polymyxin B-Immobilized Cartridge." Esteban E et al. Mediators Inflamm (2013) 2013:507539